Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 14/20 | 1.00 |
| ▸ | PIM2 | Q9P1W9 | 5/20 | 1.00 |
| ▸ | PIM3 | Q86V86 | 4/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.59 |
| ▸ | CLK2 | P49760 | 3/20 | 0.53 |
| ▸ | CLK3 | P49761 | 3/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | WNT1 | P04628 | 1/20 | 0.49 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6620394 | 0.79 | PIM1 (0.64) | PIM1PIM2PIM3FGFR1CLK2 | |
| SCHEMBL6620239 | 0.79 | PIM1 (0.64) | PIM1PIM2PIM3FGFR1CLK2 | |
| SCHEMBL29354575 | 0.78 | FGFR1 (0.77) | PIM1PIM2PIM3FGFR1CLK2 | |
| SCHEMBL758312 | 0.78 | FGFR1 (0.77) | PIM1PIM2PIM3FGFR1CLK2 | |
| SCHEMBL7255576 | 0.76 | PIM1 (0.61) | PIM1PIM2PIM3FGFR1CLK2 | |
| SCHEMBL14689417 | 0.75 | PIM1 (1.00) | PIM1PIM2PIM3CLK2CLK3 | |
| SCHEMBL3825351 | 0.75 | NPC1 (0.65) | PIM1PIM2PIM3NPC1RAB9A | |
| SCHEMBL30249428 | 0.75 | NPC1 (0.65) | PIM1PIM2PIM3NPC1RAB9A | |
| SCHEMBL16935421 | 0.74 | FGFR1 (1.00) | PIM1PIM2PIM3FGFR1CLK2 | |
| SCHEMBL25452982 | 0.74 | FGFR1 (0.61) | PIM1PIM2PIM3FGFR1CLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9850239-B2 | Pyrazolo[3,4-c]pyridine compounds and methods of use | GENENTECH, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-9850239-B2 | Pyrazolo[3,4-c]pyridine compounds and methods of use | GENENTECH, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-9850239-B2 | Pyrazolo[3,4-c]pyridine compounds and methods of use | GENENTECH, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20160159797-A1 | PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2016-06-09 | — | — | US | disclosed |
| US-20160159797-A1 | PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2016-06-09 | — | — | US | disclosed |
| US-20160159797-A1 | PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2016-06-09 | — | — | US | disclosed |
| US-9260425-B2 | Pyrazolo[3,4-c]pyridine compounds and methods of use | GENETECH, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| EP-2742046-A1 | PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2014-06-18 | — | — | EP | disclosed |
| WO-2013024002-A1 | PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-21 | — | — | WO | disclosed |
| WO-2013024002-A1 | PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-21 | — | — | WO | disclosed |
| US-20130039906-A1 | PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-14 | — | — | US | disclosed |
| US-20130039906-A1 | PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-14 | — | — | US | disclosed |
| US-20130039906-A1 | PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130039906-A1 | PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE | PIM1, PIM3, PIM2 | PIM1 1/4885PIM2 3/4885PIM3 2/4885 |
| US-20160159797-A1 | PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE | PIM1, PIM3, PIM2 | PIM1 1/4885PIM2 3/4885PIM3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.